Skip to main content
. 2023 Dec 12;27(1):108713. doi: 10.1016/j.isci.2023.108713

Figure 1.

Figure 1

TNIK was upregulated in castration-resistant prostate cancer

(A) Heatmap of the genome-wide transcript profile between (CR-LNCaP) castration tumors and (HS-LNCaP) uncastration tumors.

(B) GO analysis of transcript profile.

(C) qPCR detects mRNA expression of TNIK in (CR-LNCaP) castration tumors and (HS-LNCaP) uncastration tumors (p < 0.05). Data are represented as mean ± SD.

(D) Clinical specimens of benign prostate hyperplasia (BPH), hormone native, and CRPC were analyzed by IHC for TNIK expression. Scale bars: 200 μm. H-score of TNIK immunoreactivity in HSPC, CRPC, and their paracancerous tissues. Data were presented as median (interquartile range). Data are represented as mean ± SD. The hash symbol indicates significantly different from Para (HSPC) group (p < 0.05); an asterisk indicates significantly different from Para (CRPC) group (p < 0.05).